Real-World Efficacy of Dabrafenib Plus Trametinib for Patients With Advanced BRAF V600E-Mutated Non-Small Cell Lung Cancer
Results from the IFCT-2004 BLaDE study demonstrated that dabrafenib plus trametinib has significant efficacy among patients with advanced BRAF V600E-mutated non-small cell lung cancer (NSCLC), regardless of prior treatment status, in the real-world setting.
In this multicenter, retrospective cohort study, 163 patients received dabrafenib plus trametinib in either the first line (n = 44) or second line and beyond (n = 119) settings. The primary end point was 12-month overall survival (OS) rate in patients treated in the second line or beyond. Key secondary end points included 12-month OS rate in first-line patients and median progression-free survival (PFS) in all patients.
At a median follow-up of 27.4 months, the 12-month OS rate was 67.4% in both treatment cohorts. Median PFS was 10.4 months among second-line or beyond patients and 18.2 months among first-line patients. Due to toxicities, 10.3% of patients discontinued treatment with dabrafenib plus trametinib.
“To our knowledge, this is the largest retrospective cohort of BRAF-mutated patients reported, [and] findings confirmed the significant efficacy of D-T in combination with BRAF V600E-mutated metastatic NSCLC in pretreated and untreated patients,” concluded study authors. “These results under real-world conditions are consistent with those of other registered studies.”
Source:
Swalduz A, Beau-Faller M, Planchard D, et al. Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort. Lung Cancer. Published online: November 25, 2024. doi: 10.1016/j.lungcan.2024.108038
